263 related articles for article (PubMed ID: 15256431)
1. Transforming growth factor beta receptor type II inactivation promotes the establishment and progression of colon cancer.
Biswas S; Chytil A; Washington K; Romero-Gallo J; Gorska AE; Wirth PS; Gautam S; Moses HL; Grady WM
Cancer Res; 2004 Jul; 64(14):4687-92. PubMed ID: 15256431
[TBL] [Abstract][Full Text] [Related]
2. Transforming growth factor beta receptor type II inactivation induces the malignant transformation of intestinal neoplasms initiated by Apc mutation.
Muñoz NM; Upton M; Rojas A; Washington MK; Lin L; Chytil A; Sozmen EG; Madison BB; Pozzi A; Moon RT; Moses HL; Grady WM
Cancer Res; 2006 Oct; 66(20):9837-44. PubMed ID: 17047044
[TBL] [Abstract][Full Text] [Related]
3. Mutational inactivation of TGFBR2 in microsatellite unstable colon cancer arises from the cooperation of genomic instability and the clonal outgrowth of transforming growth factor beta resistant cells.
Biswas S; Trobridge P; Romero-Gallo J; Billheimer D; Myeroff LL; Willson JK; Markowitz SD; Grady WM
Genes Chromosomes Cancer; 2008 Feb; 47(2):95-106. PubMed ID: 17985359
[TBL] [Abstract][Full Text] [Related]
4. Effect of conditional knockout of the type II TGF-beta receptor gene in mammary epithelia on mammary gland development and polyomavirus middle T antigen induced tumor formation and metastasis.
Forrester E; Chytil A; Bierie B; Aakre M; Gorska AE; Sharif-Afshar AR; Muller WJ; Moses HL
Cancer Res; 2005 Mar; 65(6):2296-302. PubMed ID: 15781643
[TBL] [Abstract][Full Text] [Related]
5. Genetic alterations of the transforming growth factor beta receptor genes in pancreatic and biliary adenocarcinomas.
Goggins M; Shekher M; Turnacioglu K; Yeo CJ; Hruban RH; Kern SE
Cancer Res; 1998 Dec; 58(23):5329-32. PubMed ID: 9850059
[TBL] [Abstract][Full Text] [Related]
6. Activin type II receptor restoration in ACVR2-deficient colon cancer cells induces transforming growth factor-beta response pathway genes.
Deacu E; Mori Y; Sato F; Yin J; Olaru A; Sterian A; Xu Y; Wang S; Schulmann K; Berki A; Kan T; Abraham JM; Meltzer SJ
Cancer Res; 2004 Nov; 64(21):7690-6. PubMed ID: 15520171
[TBL] [Abstract][Full Text] [Related]
7. Inhibiting mutations in the transforming growth factor beta type 2 receptor in recurrent human breast cancer.
Lücke CD; Philpott A; Metcalfe JC; Thompson AM; Hughes-Davies L; Kemp PR; Hesketh R
Cancer Res; 2001 Jan; 61(2):482-5. PubMed ID: 11212236
[TBL] [Abstract][Full Text] [Related]
8. PMEPA1, a transforming growth factor-beta-induced marker of terminal colonocyte differentiation whose expression is maintained in primary and metastatic colon cancer.
Brunschwig EB; Wilson K; Mack D; Dawson D; Lawrence E; Willson JK; Lu S; Nosrati A; Rerko RM; Swinler S; Beard L; Lutterbaugh JD; Willis J; Platzer P; Markowitz S
Cancer Res; 2003 Apr; 63(7):1568-75. PubMed ID: 12670906
[TBL] [Abstract][Full Text] [Related]
9. Conditional deletion of the TGF-beta type II receptor in Col2a expressing cells results in defects in the axial skeleton without alterations in chondrocyte differentiation or embryonic development of long bones.
Baffi MO; Slattery E; Sohn P; Moses HL; Chytil A; Serra R
Dev Biol; 2004 Dec; 276(1):124-42. PubMed ID: 15531369
[TBL] [Abstract][Full Text] [Related]
10. Mutation of the type II transforming growth factor-beta receptor is coincident with the transformation of human colon adenomas to malignant carcinomas.
Grady WM; Rajput A; Myeroff L; Liu DF; Kwon K; Willis J; Markowitz S
Cancer Res; 1998 Jul; 58(14):3101-4. PubMed ID: 9679977
[TBL] [Abstract][Full Text] [Related]
11. Mutational inactivation of transforming growth factor beta receptor type II in microsatellite stable colon cancers.
Grady WM; Myeroff LL; Swinler SE; Rajput A; Thiagalingam S; Lutterbaugh JD; Neumann A; Brattain MG; Chang J; Kim SJ; Kinzler KW; Vogelstein B; Willson JK; Markowitz S
Cancer Res; 1999 Jan; 59(2):320-4. PubMed ID: 9927040
[TBL] [Abstract][Full Text] [Related]
12. Intact signaling by transforming growth factor beta is not required for termination of liver regeneration in mice.
Oe S; Lemmer ER; Conner EA; Factor VM; Levéen P; Larsson J; Karlsson S; Thorgeirsson SS
Hepatology; 2004 Nov; 40(5):1098-105. PubMed ID: 15389868
[TBL] [Abstract][Full Text] [Related]
13. Proliferation and Cdk4 expression in microsatellite unstable colon cancers with TGFBR2 mutations.
Grady WM; Willis JE; Trobridge P; Romero-Gallo J; Munoz N; Olechnowicz J; Ferguson K; Gautam S; Markowitz SD
Int J Cancer; 2006 Feb; 118(3):600-8. PubMed ID: 16108056
[TBL] [Abstract][Full Text] [Related]
14. Cell autonomous requirement for Tgfbr2 in the disappearance of medial edge epithelium during palatal fusion.
Xu X; Han J; Ito Y; Bringas P; Urata MM; Chai Y
Dev Biol; 2006 Sep; 297(1):238-48. PubMed ID: 16780827
[TBL] [Abstract][Full Text] [Related]
15. The type III transforming growth factor-beta receptor as a novel tumor suppressor gene in prostate cancer.
Turley RS; Finger EC; Hempel N; How T; Fields TA; Blobe GC
Cancer Res; 2007 Feb; 67(3):1090-8. PubMed ID: 17283142
[TBL] [Abstract][Full Text] [Related]
16. Transforming growth factor-beta regulates mammary carcinoma cell survival and interaction with the adjacent microenvironment.
Bierie B; Stover DG; Abel TW; Chytil A; Gorska AE; Aakre M; Forrester E; Yang L; Wagner KU; Moses HL
Cancer Res; 2008 Mar; 68(6):1809-19. PubMed ID: 18339861
[TBL] [Abstract][Full Text] [Related]
17. Role of TGF-beta in cancer and the potential for therapy and prevention.
Kaklamani VG; Pasche B
Expert Rev Anticancer Ther; 2004 Aug; 4(4):649-61. PubMed ID: 15270668
[TBL] [Abstract][Full Text] [Related]
18. Transforming growth factor beta1 suppresses nonmetastatic colon cancer at an early stage of tumorigenesis.
Engle SJ; Hoying JB; Boivin GP; Ormsby I; Gartside PS; Doetschman T
Cancer Res; 1999 Jul; 59(14):3379-86. PubMed ID: 10416598
[TBL] [Abstract][Full Text] [Related]
19. Aberrant transforming growth factor-beta signaling in azoxymethane-induced mouse colon tumors.
Guda K; Giardina C; Nambiar P; Cui H; Rosenberg DW
Mol Carcinog; 2001 Aug; 31(4):204-13. PubMed ID: 11536370
[TBL] [Abstract][Full Text] [Related]
20. Blockade of transforming growth factor-beta signaling suppresses progression of androgen-independent human prostate cancer in nude mice.
Zhang F; Lee J; Lu S; Pettaway CA; Dong Z
Clin Cancer Res; 2005 Jun; 11(12):4512-20. PubMed ID: 15958637
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
